Redeye is encouraged by the strong Q3 numbers including group sales hitting a new ATH.
Safe Lane Gaming publicerade den 9 november år 2022 bolagets delårsrapport för tredje kvartalet 2022...
Sales and EBIT loss +45% and -17% vs. ABGSCe Lower costs than expected, worse cash flow due to WC Sh...
EBITDA SEK 713m vs. ABGSCe SEK 718m Renewable energy project portfolio of 2,600 MW Conference call a...
Redeye leaves its comments on Idogen following the announcement of a SEK44m rights issue.
Redeye leaves its comments on Xspray Pharma’s Q3 2022 report.
Redeye will likely make minor forecast adjustments following Bredband2’s Q3 2022 report.
Fantasma Games publicerade idag, den 9e november 2022, bolagets delårsrapport för det tredje kvartal...
Sales and adj. EBITDA -1% and -3% vs. ABGSCe +1,400 customer intake q-o-q vs.
Redeye comments on Arise’s Q3 report, which was the strongest quarter in the company’s history.
Redeye retains its positive view of Infracom following its Q3 report.
Redeye will consider raising its near-term estimates on the back of this Q3 report, which crushed ou...
Active Biotechs båda NAP-projekt är på väg mot avläsning och bolaget kassa har fyllts på för att gar...
Cibus posted Q3 net operating income of EUR 26.2m, up 36% y/y on the back of acquisitions and 1% abo...
Sales in line, adj. EBIT +18% vs. consensus One-time impairment of 73m hurt net profit Buybacks to c...
Redeye comments on G5’s Q3-results where revenue and EBITDA was in line with expectations while EBIT...
NoHo Partners' Q3 EBIT was 10% above Refinitiv consensus and the company seemed confident ahead of t...
Aptahem har publicerat sin delårsrapport för tredje kvartalet 2022.
Redeye comments on Egetis’ Q3 report and reiterate our view (for now) of the company.
Analysguiden initierar bevakning av det snabbväxande SaaS-bolaget SmartCraft, vilka levererar sin lö...
